ALX Oncology (NASDAQ:ALXO – Get Free Report) posted its earnings results on Thursday. ALX Oncology has a twelve month low of $0.60 and a twelve month high of $2.66. Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. ALX Oncology Company Profile(Get Free Report)ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. Recommended StoriesReceive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.